Active ingredients: lamivudine
What it is used for
Zetlam (lamivudine) is indicated for the treatment of children (2 years and above), adolescent and adult patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication. This indication is based on changes in serological and histological markers in clinical studies of up to 2 years duration in adult patients with compensated liver disease and serological data up to 18 months in children and adolescents. Children and adolescents also require evidence of active hepatic inflammation. (see Clinical Trials). The safety and efficacy of Zetlam (lamivudine) have not been established in patients with decompensated liver disease in placebo controlled studies. However, Zetlam (lamivudine) has been shown to reduce HBV DNA levels prior to and post liver transplantation
How to take it
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
- The way to take this medicine: Oral
- Store below 30 degrees Celsius
- Store in Original Container
- Shelf lifetime is 24 Months.
Always read the label. If symptoms persist see your healthcare professional.
A peach, film-coated, capsule shaped, biconvex beveled edge tablet debossed with 'LN1' on one side and 'M' on the other side.
Images are the copyright of the Pharmacy Guild of Australia
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient lamivudine
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems